Author(s):
Latrach Fatima, El Hachemi Ouafae, Ziyyat Abderrahim, Elkhaldi Mohammed, Bouanani Nour El Houda
Email(s):
nhbouanani@yahoo.fr. , f.latrach@ump.ac.ma
DOI:
10.52711/0974-360X.2026.00271 
Address:
Latrach Fatima1, El Hachemi Ouafae2, Ziyyat Abderrahim1, Elkhaldi Mohammed3, Bouanani Nour El Houda1*
1Laboratory of Bioresources, Biotechnology, Ethnopharmacology and Health, Faculty of Sciences, Bd Med VI - BP 717 Oujda 60000 Morocco.
2Higher Institute of Nursing Professions and Health Techniques, Al Maghreb Al Arabi Street, Al Farabi Hospital, Oujda, Morocco.
3Level 1 Urban Health Center El Aounia Oujda, Morocco.
*Corresponding Author
Published In:
Volume - 19,
Issue - 4,
Year - 2026
ABSTRACT:
Background and Objectives: To respond to the health emergency caused by the Covid-19pandemic, several anti-Covid-19vaccines have been marketed. The speed of their development has prompted several questions about their safety. Therefore, the objective of this study is to carry out a systematic review of the side effects of the anti-Covid 19 vaccines, as well as their associated factors. Material and Methods: The recommendations of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were used for the selection of the studies included in this review. Articles published in English and French, aiming to identify “the side effects of anti-Covid-19 vaccines in adults” were included. Results: Most of the side effects associated with anti-Covid-19 vaccines are pain at the injection site, fatigue, myalgia and headache. Some rare side effects (myocarditis, thrombocytopenia) are more prevalent with specific types of vaccine (mRNA vaccine and adenoviral vaccine). Other serious adverse events (pulmonary embolism, pericarditis) have been reported but are rare. Conclusion: Anti-Covid 19 vaccines are reasonably safe. Further multicentre studies are needed to identify rare and long-term side effects in order to prevent or better manage them.
Cite this article:
Latrach Fatima, El Hachemi Ouafae, Ziyyat Abderrahim, Elkhaldi Mohammed, Bouanani Nour El Houda. Side Effects of Anti-Covid 19 Vaccines in Adults: A Systematic Review. Research Journal of Pharmacy and Technology. 2026;19(4):1885-5. doi: 10.52711/0974-360X.2026.00271
Cite(Electronic):
Latrach Fatima, El Hachemi Ouafae, Ziyyat Abderrahim, Elkhaldi Mohammed, Bouanani Nour El Houda. Side Effects of Anti-Covid 19 Vaccines in Adults: A Systematic Review. Research Journal of Pharmacy and Technology. 2026;19(4):1885-5. doi: 10.52711/0974-360X.2026.00271 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-4-60
REFERENCES:
1. Shah I, et al. A Systematic Review on COVID 19 Treatment and Management. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(3): 230-8. doi: 10.52711/0975-4377.2021.00039
2. Vijayashree L, Srinivasa S. Covid 19 and Stress among Students. Research Journal of Humanities and Social Sciences. 2021; 12(4): 239-4. doi: 10.52711/2321-5828.2021.00043
3. WHO. Covid-19 weekly epidemiological update: Data as received by WHO from national authorities, as of 20 December 2020, 10 am CET. 2020a.
4. Khasbage S,et al. Primary Prophylaxis of COVID-19: A Comprehensive Review of approved vaccines. Research Journal of Pharmacy and Technology. 2023; 16(2): 917-3. doi: 10.52711/0974-360X.2023.00154
5. Usha N S,et al. A Study to assess side effects of first dose of Covid-19 Vaccination among GNM students studying at JSS School of Nursing Chamarajanagar. Asian Journal of Nursing Education and Research. 2021; 11(4): 552-4. doi: 10.52711/2349-2996.2021.00129
6. Joseph J, et al. A Descriptive Study to Assess the Knowledge and Attitude towards Covid 19 Vaccination among the Adult Population visitingJubilee Mission Medical College and Research Institute, Thrissur. International Journal of Advances in Nursing Management. 2023; 11(2): 101-3. doi: 10.52711/2454-2652.2023.00023
7. Bouillon K., et al. Estimation de l’impact de la vaccination chez les personnes âgées de 75 ans et plus sur le risque de formes graves de Covid-19 en France à partir des données du Système national des données de santé (SNDS)–actualisation jusqu’au 20 juillet 2021. Rapport d’études EPI-PHARE-Groupement d’intérêt scientifique (GIS) ANSM-CNAM. 2021.
8. WHO. COVID-19 vaccinations have saved more than 1.4 million lives in the WHO European Region, a new study finds. 2024. Available on: https://www.who.int/europe/news/item/16-01-2024-covid-19-vaccinations-have-saved-more-than-1.4-million-lives-in-the-who-european-region--a-new-study-finds. Consulted on 02/09/2024.
9. Watson OJ, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. The Lancet Infectious Diseases. 2022; 22(9): 1293-1302. doi:10.1016/S1473-3099(22)00320-6
10. WHO. COVID-19 vaccine tracker and landscape. 2023. Available on: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Consulted on 02/09/2024.
11. Naik SA. Review on Pharmacovigilance. Asian J. Pharm. Res. 2020; 10(2): 123-128. doi: 10.5958/2231-5691.2020.00024.6
12. Sharma k,et al. Assessment of Adverse events following Immunization of COVID – 19 vaccination in Health Care Workers (HCWs) of Shaheed Hasan Khan Mewati Govt. Medical College Nalhar, Nuh, Haryana, India. Research Journal of Pharmacy and Technology. 2023; 16(1): 179-3. doi: 10.52711/0974-360X.2023.00033
13. WHO. Monitoring and responding to Adverse Events Following Immunization (AEFIS). 2020b. Available on: https://www.who.int/docs/default-source/covid-19-vaccines-safety-surveillance manual/covid19vaccines_manual_aefi_20210104.pdf. Consulted on 02/08/2024.
14. WHO. Global manuel on surveillance of adverse events following immunization. 2016. Availableon: https://iris.who.int/bitstream/handle/10665/206144/9789241507769_eng.pdf?sequence=1 Consulted on 17/10/2023.
15. Manjula, K. V. et Thamous, S. A Study to assess side effects of first dose of Covshield Vaccine among adults residing in Rajiv Nagar Mysore. Asian Journal of Nursing Education and Research. 2022; 12(1): 135-7. doi: 10.52711/2349-2996.2022.00029
16. TIWARI P, et al. Effectiveness and Possible Side effects of the Covishield Vaccine in Preventing Covid-19. Asian Journal of Pharmaceutical Research. 2025; 15(2): 176-2. doi: 10.52711/2231-5691.2025.00029
17. Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29, n71. doi:10.1136/bmj.n71
18. Pallot A, Rostagno S. Newcastle-Ottawa Scale: traduction française de l’échelle de qualité méthodologique pour les études de cohorte. Kinésithérapie, la Revue. 2021; 21(235): 3-4. doi:10.1016/j.kine.2019.12.046
19. Joanna Briggs Institute.Critical Appraisal tools for use in JBI Systematic Reviews. 2022. Available on: https://jbi.global/critical-appraisal-tools. Consulted on 20/02/2023
20. Sturkenboom M, et al. Cohort Monitoring of 29 Adverse Events of Special Interest Prior to and after COVID-19 Vaccination in Four Large European Electronic Healthcare Data Sources. Infectious Diseases (except HIV/AIDS); 2022. doi:10.1101/2022.08.17.22278894
21. Leechanavanichpan P, et al. Immunogenicity and adverse effects of the third booster dose with ChAdOx1 among dental care workers after receiving a full dose of CoronaVac. Mahidol Dental Journal. 2022; 42(2): 77-88. Accessed September 1, 2023. https://he02.tci-thaijo.org/index.php/mdentjournal/article/view/257157
22. Nwako AB, et al. Pattern of adverse events following immunization among recipients of first dose of ChAdOx1-S [recombinant] Covid-19 vaccine in a resource-limited country. World Journal of Advanced Research and Reviews. 2021; 12(1): 006-012. doi:10.30574/wjarr.2021.12.1.0470
23. Zafar A, et al. Adverse Effects Following COVID-19 Immunization In Khyber Pakhtunkhwa: Pakistan. Journal of Khyber College of Dentisrty. 2022; 12(2): 18-22. Accessed June 11, 2023. http://journalofkcd.com/index.php/pmsrj/article/view/53
24. Kumar R, et al. Pharmacovigilance of ChAdOx1 nCoV-19 (COVISHIELD) Vaccine after first and second dose in volunteers in Punjab, India. Asian J PharmPharmacol. 2021; 7(4): 169-177. doi:10.31024/ajpp.2021.7.4.4
25. Zhao Y, et al. Association of COVID-19 vaccination before conception with maternal liver function during early pregnancy: a cohort study of 7745 Chinese pregnant women. Emerg Microbes Infect. 11(1): 2222-2228. doi:10.1080/22221751.2022.2117100
26. Zhao Y, et al. Association of COVID-19 vaccination before conception with maternal thyroid function during early pregnancy: A single-center study in China. Journal of Medical Virology. 2023; 95(1): e28245. doi:10.1002/jmv.28245
27. Wong CKH, et al. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. PLOS Medicine. 2022; 19(6): e1004018. doi:10.1371/journal.pmed.1004018
28. Zaheri H, et al. Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination. Arch Clin Cases. 2022; 9(4): 150-153. doi:10.22551/2022.37.0904.10222
29. Khan S, et al. Post COVID-19 vaccine (SINOVAC) cerebral venous sinus thrombosis. Pakistan Journal of Neurological Sciences. 2022; 17(02). doi:10.56310/pjns.v17i02.185
30. Lv Y, Chang Y. Cytomegalovirus Proctitis Developed after COVID-19 Vaccine: A Case Report and Literature Review. Vaccines. 2022; 10(9): 1417. doi:10.3390/vaccines10091417
31. Dhamnetiya D, et al. Adverse Events Following Immunization of ChAdOx1 nCoV- 19 Vaccine Among Health Care Workers of a Tertiary Care Hospital of North India. In Review; 2022. doi:10.21203/rs.3.rs-1402713/v1
32. Mohamed WSEI, et al. Determination of Platelets Parameters among People Vaccinated with Oxford-AstraZeneca Vaccine - COVID Vaccine at Khartoum State -Sudan. Journal of Pharmaceutical Research International. 2021 December 16; 529-535. doi:10.9734/jpri/2021/v33i59A34301
33. Shahrigharahkoshan S, et al. Cutaneous LeukocytoclasticVasculitis Induction Following ChAdOx1 nCoV-19 Vaccine. Cureus. 2021; 13(10).
34. Lourenço C, et al. Polymyalgia RheumaticaAfter ChAdOx1 nCov-19 Vaccine: A Case Report. Cureus. 2022 May 26. doi:10.7759/cureus.25346
35. Kawtharani AA, et al. Longitudinal extensive transverse myelitis with sixth nerve palsy post ChAdOx1 nCov-19 vaccine: A case report and literature review. World Journal of Advanced Research and Reviews. 2021; 12(2): 526-538. doi:10.30574/wjarr.2021.12.2.0613
36. Urban N, et al. Raynaud’s Phenomenon after COVID-19 Vaccination: Causative Association, Temporal Connection, or Mere Bystander? Case Rep Dermatol. 2021; 13(3): 450-456. doi:10.1159/000519147
37. Bazrafshan H, et al. A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination. Turk J Phys Med Rehabil. 2022;68(2):295-299. doi:10.5606/tftrd.2022.9984
38. Zamzami OS, et al. Post-COVID-19 Vaccine Parosmia: A Case Report. Cureus. 2021 Dec 9. doi:10.7759/cureus.20292
39. Pisani D, et al. Sudden sensorineural hearing loss after covid-19 vaccine; A possible adverse reaction? Otolaryngology Case Reports. 2021; 21: 100384. doi:10.1016/j.xocr.2021.100384
40. Shapiro Ben David S, et al. Immediate side effects of Comirnaty COVID-19 vaccine: A nationwide survey of vaccinated people in Israel, December 2020 to March 2021. Eurosurveillance. 2022; 27(13). doi:10.2807/1560-7917.ES.2022.27.13.2100540
41. Riad A, et al. Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study. Pharmaceuticals. 2021; 14(10): 1049. doi:10.3390/ph14101049
42. Olivos EN, et al. Reactivity and Safety of BioNTech/Pfizer® Vaccine Anti-SARS-CoV-2, in Health Personnel from the Mexican State of Guanajuato. Biomed Pharmacol J. 2022; 15(2): 993-1003. doi:10.13005/bpj/2435
43. Dabbousi AA, et al. Menstrual abnormalities post-COVID vaccination: a cross-sectional study on adult Lebanese women. Ir J Med Sci. 2023; 192(3): 1163-1170. doi:10.1007/s11845-022-03089-5
44. Visser C, et al. The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists. ThrombHaemost. 2022; 122(3): 377-385. doi:10.1055/s-0042-1742628
45. Tanzilli A, et al. COV-BT Ire study : Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors. NeurologicalSciences. 2022; 43(6): 3519‑3522. https://doi.org/10.1007/s10072-022-06054-3.
46. Syrigos N, et al. Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event. Vaccines. 2022; 10(5): 745. doi:10.3390/vaccines10050745
47. Etuk AS, et al. A Rare Case of Myocarditis After the first dose of Moderna Vaccine in a Patient With Two Previous COVID-19 Infections. Cureus. 2022 May 7. doi:10.7759/cureus.24802
48. Alharbi F, et al. Case Study of COVID-19 Vaccine-Associated Myocarditis. Asian Journal of Case Reports in Medicine and Health. 2022; 7(4): 25-32. Accessed June 12, 2023. http://articlegates.uk/id/eprint/1811/
49. Sciaccaluga C, et al. Case Report: Two Case Reports of Acute Myopericarditis After mRNA COVID-19 Vaccine. Front Cardiovasc Med. 2022;9:827237. doi:10.3389/fcvm.2022.827237
50. Teran Brage E, et al. Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review. Current Problems in Cancer: Case Reports. 2022; 6: 100153. doi:10.1016/j.cpccr.2022.100153
51. Alania-Torres E, et al. Case Report: Probable Myocarditis After Covid-19 mRNA Vaccine in a Patient With Arrhythmogenic Left Ventricular Cardiomyopathy. Front Cardiovasc Med. 2021; 8: 759119. doi:10.3389/fcvm.2021.759119
52. Gaignard ME, et al. Autoimmune Hematologic Disorders in Two Patients After mRNA COVID-19 Vaccine. Hemasphere. 2021; 5(8): e618. doi:10.1097/HS9.0000000000000618
53. Shimada Y, et al. A case of hemophagocyticlymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination. Medicine (Baltimore). 2022; 101(43): e31304. doi:10.1097/MD.0000000000031304
54. Banamah TA, et al. Severe Rhabdomyolysis Complicated With Acute Kidney Injury Required Renal Replacement Therapy After Pfizer COVID-19 Vaccine. Cureus. 2022 May 22. doi:10.7759/cureus.25199
55. Magen E, et al. Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis. Vaccines. 2022; 10(7): 1135. doi:10.3390/vaccines10071135
56. Ajmera K, et al. Gastrointestinal Complications of COVID-19 Vaccines. Cureus. 2022 Apr 12. doi:10.7759/cureus.24070
57. Ahmed F, et al. Multiple Keratoacanthomas Following Moderna Messenger RNA-1273 COVID-19 Vaccination Resolved With 5-Fluorouracil Treatment: Case Report. JMIR Dermatol. 2022; 5(4): e41739. doi:10.2196/41739
58. Infante M, et al. BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report. Vaccines. 2022; 10(7): 1096. doi:10.3390/vaccines10071096
59. Kita A, et al. Psychiatric Adverse Reaction to COVID-19 Vaccine Booster Presenting as First-Episode Acute Mania with Psychotic Features: A Case Report. In Review; 2022. doi:10.21203/rs.3.rs-2086934/v1
60. Renemane L, et al. First Episode Psychosis Following COVID-19 Vaccination: a Case Report. PsychiatriaDanubina. 2022; 34: 56-59.
61. Guina J, et al. Bipolar I Disorder Exacerbation Following COVID-19 Vaccination. InnovClinNeurosci. 2022; 19(7-9): 9-11. Accessed March 9, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507143/
62. Ibrahim F, et al. Side Effects of COVID-19 Vaccines (Pfizer, AstraZeneca) in Saudi Arabia, Eastern Province. Cureus. 2022 July 26. doi:10.7759/cureus.27297
63. Ruggiero R, et al. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance. Front Immunol. 2022; 13: 956825. doi:10.3389/fimmu.2022.956825
64. Akhlaghi H, et al. Epidemiology, clinical presentations and outcome of patients presenting to the emergency department after a COVID‐19 vaccination: An observational study. Emerg Med Australas. 2022 May 26; 10.1111/1742-6723.14016. doi:10.1111/1742-6723.14016
65. Rosner CM, et al. Myocarditis Temporally Associated With COVID-19 Vaccination. Circulation. 2021; 144(6): 502-505. doi:10.1161/CIRCULATIONAHA.121.055891
66. Lazarus R, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. The Lancet. 2021; 398(10318): 2277-2287. doi:10.1016/S0140-6736(21)02329-1
67. Akpandak I, et al. Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine. JAMA Netw Open. 2022; 5(11): e2242240. doi:10.1001/jamanetworkopen.2022.42240
68. Kaur RJ, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Ind J ClinBiochem. 2021; 36(4): 427-439. doi:10.1007/s12291-021-00968-z
69. Castaldo M, et al. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. The Journal of Headache and Pain. 2022; 23(1): 41. doi:10.1186/s10194-022-01400-4
70. Jameie M, et al. Characteristics of headaches attributed to SARS-CoV-2 vaccination and factors associated with its frequency and prolongation: a cross-sectional cohort study. Front Neurol. 2023; 14: 1214501. doi:10.3389/fneur.2023.1214501
71. Chen M, et al. Safety of SARS-CoV-2 vaccines : A systematic review and meta-analysis of randomized controlled trials. InfectiousDiseases of Poverty, 2021; 10(1): 94. https://doi.org/10.1186/s40249-021-00878-5.
72. ANSM. Enquête de pharmacovigilance du vaccin VAXZEVRIA® Rapport n°18: période du 31 décembre 2021 au 25 août 2022 CRPV d’Amiens - CRPV de Rouen. 2022. Available on: https://ansm.sante.fr/dossiers-thematiques/covid-19-vaccins/covid-19-suivi-hebdomadaire-des-cas-deffets-indesirables-des-vaccins.Consulted on 10/10/2023
73. Mes vaccins.VAXZEVRIA ASTRAZENECA 2023a. Available on :https://www.mesvaccins.net/web/vaccines/650-vaxzevria-astrazenec. Consulted on 15/10/2023.
74. ANSM. Enquête de pharmacovigilance du vaccin Pfizer – BioNTechComirnaty Focus mensuel n°1 situations spécifiques jusqu’au 30 septembre 2021 CRPV de Bordeaux, CRPV de Marseille, CRPV de Toulouse, CRPV de Strasbourg. 2021. Available on :https://ansm.sante.fr/uploads/2021/10/22/20211021-covid-19-vaccins-pfizer-focus-1-2.pdf Consulted on 08/09/2023
75. Botton J, et al. Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France. Annals of internalmedicine, 2022; 175(9): 1250-1257.
76. ANSM. Suivi des cas d’effets indésirables des vaccins COVID-19 Actualisation au 8/6/2023. 2023. Available on: https://ansm.sante.fr/uploads/2023/08/28/2023-06-08-fiche-de-synthese-61-vaccins-covid.pdf.Consulted on 12/10/2023.
77. Mes vaccins. CORONAVAC SINOVAC COVID-19 VACCINE. 2023b. Available on: https://www.mesvaccins.net/web/vaccines/651-coronavac-sinovac-covid-19-vaccine. Consulted on 12/11/2023.
78. Fakir J,et al. Survey Based Assessment of Adverse Effect in Covid-19 Vaccination Breakthrough Infections. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(3): 195-0. doi: 10.52711/2231-5659.2023.00034
79. Qiao Y, et al. Safety profile of COVID-19 vaccines in pregnant and postpartum women in brazil. 2021 Dec 17; 2021.12.14.21267777. doi:10.1101/2021.12.14.21267777
80. Oudjedi A, et al. Reported COVID-19 vaccines side effects among Algerian athletes: a comparison between inactivated virus, adenoviral vector, and mRNA COVID-19 vaccines. The Physician and Sportsmedicine. 2024; 52(2): 134-146. doi:10.1080/00913847.2023.2186691
81. Al-QazazHKh, et al. COVID-19 vaccination, do women suffer from more side effects than men? A retrospective cross-sectional study. Pharm Pract (Granada). 2022; 20(2): 2678. doi:10.18549/PharmPract.2022.2.2678
82. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020; 11(1): 32. doi:10.1186/s13293-020-00308-5
83. Beatty AL, et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Network Open. 2021; 4(12): e2140364. doi:10.1001/jamanetworkopen.2021.40364
84. Wahyudi F, et al. Adverse events following immunization (AEFI): COVID-19 vaccine dose and characteristics in Central Java, Indonesia. Germs. 2023; 13(1): 40-49. doi:10.18683/germs.2023.1365
85. Ferrara P, et al. Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies. Public Health. 2022; 203: 97-99. doi:10.1016/j.puhe.2021.12.013
86. Iguacel I, et al. Association between COVID-19 Vaccine Side Effects and Body Mass Index in Spain. Vaccines. 2021; 9(11): 1321. doi:10.3390/vaccines9111321
87. Fateh HL, et al. Association between diet quality and BMI with side effects of Pfizer-BioNTech COVID-19 vaccine and SARS-CoV-2 immunoglobulin G titers. Nutrition and Food Science. 2023; 53(4): 738-751. doi:10.1108/NFS-09-2022-0338
88. Hallam J, et al. Exercise after influenza or COVID-19 vaccination increases serum antibody without an increase in side effects. Brain, Behavior, and Immunity. 2022; 102: 1-10. doi:10.1016/j.bbi.2022.02.005
89. Lai FTT, et al. Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong. Nat Commun. 2022; 13(1): 411. doi:10.1038/s41467-022-28068-3
90. Seyed Alinaghi S, et al. Complications of COVID-19 vaccines during pregnancy; a systematic review. Archives of Academic Emergency Medicine, 2022; 10(1).
91. Codoni G, et al. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Reports. 2023; 5(1): 100605. doi:10.1016/j.jhepr.2022.100605
92. Safary A, et al. SARS-CoV-2 vaccine-triggered autoimmunity: Molecular mimicry and/or bystander activation of the immune system. Bioimpacts. 2023; 13(4): 269-273. doi:10.34172/bi.2023.27494
93. PENG, Kuan, LI, Xue, YANG, Deliang, et al. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. EClinicalMedicine, 2023, vol. 63.
94. Sachinidis A, Garyfallos A. COVID‐19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age‐associated B cells. Int J RheumDis. 2022; 25(1): 83-85. doi:10.1111/1756-185X.14238
95. Yang C, et al. Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates. Vaccine. 2023; 41(49): 7450-7459. doi:10.1016/j.vaccine.2023.11.011